SEC Form 3 · accession 0001178913-16-006514
Artemis Therapeutics, Inc. · ATMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Israel Alfassi
Director
Period of report
Aug 23, 2016
Accepted (ET)
Sep 15, 2016 · 11:48 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,500,000 | D | ||
| Series B Convertible Preferred StockF1 | holding | — | — | — | 154 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Such shares of Series B Preferred Stock are exercisable into 11,172,976 shares of Common Stock.